Guest guest Posted April 5, 2006 Report Share Posted April 5, 2006 ZAP 70 methylation: a new prognostic marker in CLL Oscier, M.D. Royal Bournemouth Hospital (United Kingdom) Abstract: Most patients with chronic lymphocytic leukemia (CLL) are asymptomatic at diagnosis and wish to know the likely natural history of their disorder. ZAP70 is signaling molecule essential for the function of a subset of normal white blood cells (T lymphocytes). It is also expressed in the leukemic cells of a subset of patients with CLL and correlates with a shorter time from diagnosis to first treatment and with shorter survival. There is increasing evidence that ZAP 70 expression contributes to the poorer prognosis of ZAP70 positive cases and is not simply a marker of aggressive disease. Recent data suggest that ZAP 70 may also be a target for therapy. Most laboratories measuring ZAP70 expression use a flow cytometric assay, which is widely available, rapid and inexpensive. Unfortunately this assay is not standardized such that a sample may be considered positive for ZAP 70 in one laboratory and negative in another. We have shown that a modification of the ZAP70 gene (DNA methylation) correlates closely with ZAP70 expression measured by flow cytometry. The methylation assay is not subject to many of the factors such as sample age, which can affect the flow cytometric assay. However, the methylation assay we have used so far is only semi quantitative and gives an equivocal result in about 6% of cases. We propose to use a rapid, sensitive and fully quantitative method (Pyrosequencing) for detecting ZAP70 methylation. The prognostic value of this assay will then be tested retrospectively in a cohort of 300 patients with prolonged follow up, managed at a single center, and prospectively in 300 patients entered into the UK CLL4 randomised trial for previously untreated patients. Multivariate analysis will be employed to determine whether ZAP 70 methylation provides additional information to known prognostic factors. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.